Reify Health, which makes cloud-based tools for clinical trial research, raises a $220M Series D co-led by Altimeter Capital and Coatue at a $4.8B+ valuation
Michelle F Davis / Bloomberg :
Context & Ripple Effects
Reify Health's valuation has doubled in eight months: the $220M Series C led by Coatue at $2.2B in August 2021 is now followed by a $220M Series D co-led by Altimeter and Coatue at $4.8B-plus, capping a run that began with a $30M Series B from Battery Ventures in 2020 when total funding was under $40M.
The round lands in a crowded lane of well-capitalized clinical trial software rivals: Medable raised a $304M Series D led by Blackstone Growth and Tiger Global at $2.1B, Evidation Health pulled in a $153M round at a $1B-plus valuation for its virtual-trial data aggregation, and Clarify Health raised a $150M Series D weeks before this one — crossover funds like Coatue and Altimeter are now the recurring names across the category.
First-order effects
- Reify Health now carries the largest disclosed valuation among the clinical trial software peers in this coverage — more than double Medable's $2.1B and over four times Evidation's $1B-plus — giving it a currency advantage in talent and potential acquisitions.
- Coatue doubles down within eight months, moving from sole Series C lead to co-leading the Series D alongside Altimeter, whose entry signals crossover funds treating trial software as a late-stage, pre-IPO asset class.
Second-order effects
- Medable, Evidation, and Clarify Health face pressure to justify their own smaller valuations against Reify's $4.8B-plus mark, likely pushing them toward larger rounds or consolidation plays with the same crossover investor base.
- Pharma and CRO buyers of trial software see a market where three-plus vendors are each holding $150M-plus war chests, strengthening their hand on pricing and accelerating vendor consolidation expectations.
Third-order effects
- If the pattern holds, clinical trial software consolidates into a few platform-scale companies backed by the same handful of crossover funds — the Coatue-Altimeter-Blackstone-Tiger overlap across this coverage suggests category winners are being financed in parallel rather than competing for distinct capital.
- The velocity from sub-$40M raised in 2020 to $4.8B-plus valued by 2022 points toward a sector where decentralized trial infrastructure becomes a standard pharma procurement line item, with valuations set by crossover funds ahead of any public-market test.
The trend: Clinical trial software is consolidating into a crossover-funded platform race, with Coatue and peers marking up the same category at accelerating valuations ahead of a likely public-market window.